INSTITUT DE CANCEROLOGIE DE L’OUEST (ICO), SITE P PAPIN

The INSTITUT DE CANCEROLOGIE DE L’OUEST (ICO) is exploring innovative immunotherapy combined with PARP inhibition to treat advanced gynecologic cancers, seeking better disease control after standard chemotherapy.

• Selection of the most effective dostarlimab plus niraparib strategy
• Comparison of combination therapy versus niraparib alone

These studies aim to identify a superior therapeutic option that can extend survival for patients with metastatic or recurrent endometrial and ovarian carcinosarcoma.

Research at the site evaluates the safety and optimal dosing of new agents when paired with established compounds, addressing a broad range of solid tumors including lung, liver, and skin cancers.

• Determination of the recommended phase 2 dose for DB-1311 with BNT327
• Assessment of DB-1311 combined with DB-1305 for tolerability

The goal is to establish safe, effective combination regimens that can be advanced to later-stage testing for cancers such as non‑small cell lung cancer and hepatocellular carcinoma.

Focused investigations target rare and aggressive forms of gynecologic cancer, employing molecular profiling to guide therapy selection and improve patient outcomes.

• Evaluation of novel agents in metastatic or recurrent endometrial and ovarian carcinosarcoma
• Integration of biomarker‑driven approaches to personalize treatment

By tailoring therapies to the genetic characteristics of each tumor, the program seeks to offer new hope for patients with limited treatment options.